Updated Evaluation of the Safety, Efficacy and Tolerability of Pirfenidone in the Treatment of Idiopathic Pulmonary Fibrosis
Drug, Healthcare and Patient Safety · 2020-05 · Volume 12 · 85-94
DOI: 10.2147/dhps.s224007 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug, Healthcare and Patient Safety, 2020-05. Verfasst von Swati Gulati und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
- Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Zitieren
APA
Gulati, S., & Luckhardt, T. R. (2020). Updated Evaluation of the Safety, Efficacy and Tolerability of Pirfenidone in the Treatment of Idiopathic Pulmonary Fibrosis. Drug, Healthcare and Patient Safety, Volume 12, 85-94. https://doi.org/10.2147/dhps.s224007
Vancouver
Gulati S, Luckhardt TR. Updated Evaluation of the Safety, Efficacy and Tolerability of Pirfenidone in the Treatment of Idiopathic Pulmonary Fibrosis. Drug, Healthcare and Patient Safety. 2020;Volume 12:85-94. doi:10.2147/dhps.s224007
BibTeX
@article{Gulati2020,
author = {Gulati, Swati and Luckhardt, Tracy R},
title = {Updated Evaluation of the Safety, Efficacy and Tolerability of Pirfenidone in the Treatment of Idiopathic Pulmonary Fibrosis},
journal = {Drug, Healthcare and Patient Safety},
year = {2020},
volume = {Volume 12},
pages = {85--94},
doi = {10.2147/dhps.s224007}
}
EUVIMED